[en] OBJECTIVES: To investigate the characteristics and one-year outcomes following sirolimus-eluting CYPHER Select Plus stent (SES) implantation in small (SmVD) and non-small vessel disease (NSmVD) in the international e-SELECT registry. BACKGROUND: Large-scale registry data are lacking on DES outcomes in SmVD treatment. METHODS: There were 4,700 SmVD (at least one vessel with estimated reference vessel diameter [RVD] < 2.5 mm, excluding 283 patients with unknown RVD vessels) and 10,139 NSmVD only patients. RESULTS: The SmVD population was older, with more women, diabetics, and vessels treated, higher mean Charlson Comorbidity Index score (CCI), shorter lesions, and less STEMI presentation. The 1-year stent thrombosis (ST) rate (primary end-point), was significantly higher (1.3% vs. 0.7%) in SmVD versus NSmVD, mainly driven by early events. One-year major adverse cardiac event (MACE), myocardial infarction (MI), and clinically indicated target-lesion revascularization (TLR) rates were significantly higher in SmVD although death and major bleeding rates were similar in both groups. Complication rates were similar between pure (3,188 patients; only RVD < 2.5 mm) and mixed (1,795 patients; some RVD < 2.5 mm or unknown RVD) SmVD. Multivariate predictors for 1-year MACE in SmVD included saphenous vein graft or bifurcation lesions, major bleeding, any antiplatelet therapy discontinuation within 1 month, age, number of stents implanted, CCI, acute coronary syndrome, and insulin-dependent diabetes mellitus. CONCLUSION: SES implantation for SmVD occurs more frequently in women, diabetics, and those with multivessel disease and comorbidities. One-year ST, MACE, MI, and clinically indicated TLR rates are higher, although low overall, in SmVD or mixed SmVD patients while death rates are similar to NSmVD.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Gao, Runlin
Abizaid, Alexandre
Banning, Adrian
Bartorelli, Antonio L.
Dzavik, Vladimir
Ellis, Stephen
Jeong, Myung Ho
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Spaulding, Christian
Urban, Philip
Language :
English
Title :
One-year outcome of small-vessel disease treated with sirolimus-eluting stents: a subgroup analysis of the e-SELECT registry.
Biondi-Zoccai G, Moretti C, et al. Percutaneous coronary intervention for small vessel coronary artery disease. Cardiovasc Revasc Med 2010; 11: 189-198.
Bartorelli AL, Serruys PW, Miquel Hebert K, et al. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials. Catheter Cardiovasc Interv 2010; 76 (1): 60-66.
Wykrzykowska JJ, Serruys PW, Onuma Y, et al. Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy. JACC Cardiovasc Interv 2009; 2 (9): 861-870.
Godino C, Furuichi S, Latib A, et al. Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE registry). Am J Cardiol 2008; 102: 1002-1008.
Colombo A, Chieffo A,. Drug-eluting stent update 2007: Part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarction, and multivessel disease). Circulation 2007; 116: 1424-1432.
Habara S, Mitsudo K, Goto T, et al. The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis. Heart 2008; 94 (9): 1162-1165.
Hsieh IC, Chien CC, Chang HJ, et al. Acute and long-term outcomes of stenting in coronary vessel > 3.0 mm, 3.0-2.5 mm, and < 2.5 mm. Catheter Cardiovasc Interv 2001; 53: 314-322.
Süselbeck T, Latsch A, Siri H, et al. Role of vessel size as a predictor for the occurrence of in-stent restenosis in patients with diabetes mellitus. Am J Cardiol 2001; 88: 243-247.
Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-754.
Koh AS, Chia S, Choi LM, et al. Long-term outcomes after coronary bare-metal-stent and drug-eluting-stent implantations: A 'real-world' comparison among patients with diabetes with diffuse small vessel coronary artery disease. Coron Artery Dis 2011; 22 (1): 96-99.
Costa MA, Sabate M, Staico R, et al. Anatomical and physiologic assessments in patients with small coronary artery disease: Final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial. Am Heart J 2007; 153 (2):296. e1-e7.
O'Connor NJ, Morton JR, Birkmeyer JD, et al. Effect of coronary artery diameter in patients undergoing coronary bypass surgery. Circulation 1996; 93: 652-655.
Cannon LA, Kereiakes DJ, Mann T, et al. A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: The PERSEUS Small Vessel trial. EuroIntervention 2011; 6 (8): 920-927.
Ito H, Hermiller JB,. Percutaneous coronary intervention for small-vessel coronary disease: Highlight on the everolimus-eluting stent. Expert Rev Cardiovasc Ther 2010; 8 (9): 1239-1245.
Ortolani P, Ardissino D, Cavallini C, et al. Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy). Am J Cardiol 2005; 96 (10): 1393-1398.
Qiao SB, Hou Q, Xu B, et al. Comparison of drug-eluting stent and bare-mental stent in the complex small vessel intervention. Chin Med J (Engl) 2006; 119 (7): 596-600.
Devito FS, Sousa AG, Feres F, et al. Comparative analysis of intimal hyperplasia after sirolimus-eluting stent and thin-strut bare-metal stent implantation in small coronary arteries. Arq Bras Cardiol 2006; 86 (4): 268-275.
Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs. uncoated stents for prevention of restenosis in small coronary arteries: A randomized trial. JAMA 2004; 292: 2727-2734.
Jabara R, Gradman M, Chen zjp, et al. Clinical and angiographic features of small vessel stenting in the drug-eluting stent era. Clin Cardiol 2009; 32 (6): e40-e45.
Tanimoto S, Daemen J, Tsuchida K, et al. Two-year clinical outcome after coronary stenting of small vessels using 2.25mm sirolimus and paclitaxel-eluting stents: Insight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv 2007; 69 (1): 94-103.
Holmes DR Jr, Kereiakes DJ,. The approach to small vessels in the era of drug-eluting stents. Rev Cardiovasc Med 2005; 6 (Suppl 1): S31-S37.
Moses JW, Nikolsky E, Mehran R, et al. Safety and efficacy of the 2.25 mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: The SIRIUS 2.25 trial. Am J Cardiol 2006; 98: 1455-1460.
Meier B, Sousa E, Guagliumi G, et al. Sirolimus-eluting coronary stents in small vessels. Am Heart J 2006; 151 (5):1019. e1-e7.
Hermiller JB, Fergus T, Pierson W, et al. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: A post hoc analysis of the SPIRIT III randomized trial. Am Heart J 2009; 158 (6): 1005-1010.
Mauri L, Orav EJ, O'Malley AJ, et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005; 111: 321-327.
Elezi S, Kastrati A, Neumann FJ, et al. Vessel size and long-term outcome after coronary stent placement. Circulation 1998; 98: 1875-1880.
Urban P, Abizaid A, Banning A, et al. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population. A report from the-SELECT (multi-center post-market surveillance) registry. J Am Coll Cardiol 2011; 57 (13): 1445-1454.
Worthley SG, Abizaid A, Banning A, et al. One-year clinical outcomes after sirolimus-eluting coronary stent implantation for acute myocardial infarction in the worldwide e-SELECT registry. J Interv Cardiol 2012 Jun; 25 (3): 253-61, doi: 10.1111/j.1540-8183.2011.00705.x. Epub 2012 Feb 20.
Abizaid A, Costa JR Jr, Banning A, et al. The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: Insights from the e-SELECT (Multicenter Post-Market Surveillance) registry. JACC Cardiovasc Interv 2012; 5 (1): 64-71.
Cuculi F, Banning AP, Abizaid A, et al. Outcomes in patients undergoing multivessel percutaneous coronary intervention using sirolimus-eluting stents: A report from the e-SELECT registry. Euro Intervention 2011; 7 (8): 962-968.
Hong YJ, Jeong MH, Abizaid A, et al. Sirolimus-eluting coronary stents in octogenarians: A 1-year analysis of the worldwide e-SELECT Registry. JACC Cardiovasc Interv 2011; 4 (9): 982-991.
Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006-1017.
Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
Biondi-Zoccai GG, Sangiorgi GM, Antoniucci D, et al. Taxus in Real-life Usage Evaluation Study. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients: Design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in Real-life Usage Evaluation (TRUE) Study. Int J Cardiol 2007; 117: 349-354.
Elezi S, Dibra A, Mehilli J, et al. Vessel size and outcome after coronary drug-eluting stent placement: Results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006; 48 (7): 1304-1309.
De Luca G, Suryapranata H, van't Hof AW, et al. Comparison between stenting and balloon angioplasty in patients undergoing primary angioplasty of small coronary vessels. Am Heart J 2006; 152 (5): 915-920.
Togni M, Eber S, Widmer J, et al. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: A subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007; 50 (12): 1123-1131.
Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus or paclitaxel eluting stents. Circulation 2006; 113 (19): 2293-2300.
Rodriguez-Granillo GA, Valgimigli M, Garcia-Garcia HM, et al. One-year clinical outcome after coronary stenting of very small vessels using 2.25 mm sirolimus and paclitaxel eluting stents: A comparison between the RESEARCH and T-SEARCH registries. J Invasive Cardiol 2005; 17 (8): 409-412.
Seabra-Gomes R, Sousa JE, Sousa A, et al. Small coronary arteries treated with sirolimus eluting stents: One-year results of the PORTO multicentre registry. Euro Intervention 2007; 3 (2): 197-205.
Mehilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel and sirolimus eluting stents in small coronary arteries. Eur Heart J 2006; 27: 260-266.
Li JJ, Xu B, Yang YJ, et al. Drug-eluting stent for the treatment of small coronary lesion: Comparison between sirolimus and paclitaxel eluting stent. Chin Med J (Engl) 2007; 120 (7): 569-573.
Nikolsky E, Moses JW, Mahran R, et al. Safety and efficacy of the 2.25-mm sirolimus-eluting BX Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial. Am J Cardiol 2006; 98: 1455-1460.
Bucalo R, Capranzano P, Conti G, et al. Sirolimus versus paclitaxel eluting stents in small coronary vessels: Long term outcomes from a single-center registry. J Cardiovasc Med 2010; 11 (5): 365-368.
Ferrer Garcia MC, Moreno R, Pérez Vizcayno MJ, et al. Failure in the implantation of drug-eluting stents. Frequency and related factors. Med Intensiva 2007; 31: 423-427.
Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215-1223.
Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362 (9390): 1093-1099.
Schampaert E, Cohen EA, Schlüter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43 (6): 1110-1115.
Kaneda H, Ako J, Terashima M, et al. Sirolimus eluting stent implantation in small coronary arteries: A three dimensional intravascular ultrasound study from the SIRIUS trial. Int J Cardiol 2010; 138 (2): 126-130.
Unverdorben M, Kleber FX, Heuer H, et al. Treatment of small coronary arteries with a paclitaxel coated balloon catheter. Clin Res Cardiol 2010; 99 (3): 165-174.
Huang P, Levin T, Kabour A, et al. Acute and late outcome after use of 2.5 mm intracoronary stents in small (<2.5 mm) coronary arteries. Catheter Cardiovasc Interv 2000; 49: 121-126.
Umeda H, Iwase M, Gochi T, et al. Safety and efficacy of 2.5 mm sirolimus eluting stent implantation at lower deployment pressures in very small vessels (<2.5 mm). Coron Artery Dis 2009; 20 (2): 163-168.
Turco MA, Ormiston JA, Popma JJ, et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: One-year results from the TAXUS ATLAS program. JACC Cardiovasc Interv 2008; 1 (6): 699-709.
Hausleiter J, Kastrati A, Mehilli J, et al. Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. J Am Coll Cardiol 2001; 40: 882-889.
Raisuke I, Yuji I, Akiyoshi M, et al. Predictors of restenosis after implantation of 2.5 mm stents in small coronary arteries. Circ J 2004; 68 (3): 236-240.
Iijima R, Ikari Y, Wada M, et al. Cutting balloon angioplasty is superior to balloon angioplasty or stent implantation for small coronary artery disease. Coron Artery Dis 2004; 15 (7): 435-440.
Lee CW, Suh J, Lee SW, et al. Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries. Catheter Cardiovasc Interv 2007; 69 (6): 821-825.
Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus eluting stent implantation. Circulation 2004; 109 (16): 1930-1932.
